The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial infarction (MI), according to a study published ...

Mankind Pharma, India's fourth largest pharmaceutical company, for its flagship brand, Nimulid Strong for pain relief gel & spray has roped in film actor Rajkummar Rao as the new brand ambassador. The ...

In May, Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new funding from Royalty Pharma, the biotech has withdrawn that runway end ...

Mankind Pharma Shares Rise by 2% With the stock price at Rs 2511.10, Mankind Pharma shows a positive price movement in today's session.

Mankind Pharma is focused on expanding its presence in the gastrointestinal and dermatology segments this year, as it looks at expanding its presence in the chronic segments, managing director ...

Mankind Pharma on Wednesday reported a 10% year-on-year (YoY) decrease in net profit to Rs 429 crore in Q4 FY24, attributed to one-time costs related to the integration of BSV. Revenue from ...

Indian drugmaker Mankind Pharma reported a fourth-quarter profit that beat analysts' estimates on Wednesday, driven by strong domestic demand for its drugs to treat long-term illnesses.

Review the current valuation for Mankind Pharma Ltd (MANKIND:XNSE) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

The price of empagliflozin, a commonly prescribed diabetes drug, has been slashed by a staggering 90% in India. This significant reduction, made possible by the entry of generic versions, is poised to ...